Mitralklappenerkrankung des Hundes im asymptomatischen Stadium: Behandeln oder nicht behandeln?

Die Mitralklappenendokardiose ist die häufigste Herzerkrankung des Hundes. Oftmals ist sie durch einen jahrelangen präklinischen Verlauf gekennzeichnet und gerade die Behandlung dieses asymptomatischen Stadiums wird selbst in Fachkreisen kontrovers diskutiert. Die folgende Veröffentlichung gibt eine aktuelle Literaturübersicht zur Behandlung der Mitralendokardiose im asymptomatischen Stadium. Sie soll dem Praktiker eine therapeutische Entscheidung nach aktuellstem Wissensstand erleichtern.

• Literatur

• 1 Atkins C, Keene BW, Brown WA. Results of the veterinary enalapril trial to prove reduction in onset of heart failure in dogs chronically treated with enalapril alone for compensated, naturally occurring mitral valve insufficiency. J Am Vet Med Assoc 2007; 231 (7): 1061-1069
• 2 Atkins C, Bonagura J, Ettinger S et al. Guidelines for the diagnosis and treatment of canine chronic valvular heart disease. J Vet Intern Med 2009; 23 (6): 1142-1150
• 3 Atkins C, Häggström J. Pharmacologic management of myxomatous mitral valve disease in dogs. J Vet Cardiol 2012; 14 (1): 165-184
• 4 Bavegems V, Van Caelenberg A, Duchateau L et al. Vertebral heart size ranges specific for whippets. Vet Radiol Ultrasound 2005; 46 (5): 400-403
• 5 Beardow AW, Buchanan JW. Chronic mitral valve disease in cavalier King Charles spaniels: 95 cases (1987–1991). J Am Vet Med Assoc 1993; 203 (7): 1023-1029
• 6 Bernay F, Bland JM, Häggström J et al. Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med 2010; 24 (2): 331-341
• 7 Borgarelli M, Crosara S, Lamb K et al. Survival characteristics and prognostic variables of dogs with preclinical chronic degenerative mitral valve disease attributable to myxomatous degeneration. J Vet Intern Med 2012; 26 (1): 69-75
• 8 Buchanan JW, Bücheler J. Vertebral scale system to measure canine heart size in radiographs. J Am Vet Med Assoc 1995; 206 (2): 194-199
• 9 Buchanan J. Prevalence of cardiovascular disorders. In: Fox PR, Sisson DD, Moise N, eds. Textbook of Canine and Feline Cardiology. Philadelphia: Saunders; 1999
• 10 Chetboul V, Lefebvre HP, Sampedrano CC et al. Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded, and randomized study. J Vet Intern Med 2007; 21 (4): 742-253
• 11 Chetboul V, Serres F, Tissier R et al. Association of plasma N-terminal pro-B-type natriuretic peptide concentration with mitral regurgitation severity and outcome in dogs with asymptomatic degenerative mitral valve disease. J Vet Intern Med 2009; 23 (5): 984-994
• 12 Farquharson CA, Struthers AD. Aldosterone induces acute endothelial dysfunction in vivo in humans: evidence for an aldosterone-induced vasculopathy. Clin Sci (Lond) 2002; 103 (4): 425-431
• 13 Gelzer AR, Kraus MS, Rishniw M et al. Combination therapy with digoxin and diltiazem controls ventricular rate in chronic atrial fibrillation in dogs better than digoxin or diltiazem monotherapy: a randomized crossover study in 18 dogs. J Vet Intern Med 2009; 23 (3): 499-508
• 14 Häggström J, Hansson K, Karlberg BE et al. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation. Am J Vet Res 1996; 57 (11): 1645-1652
• 15 Häggström J, Hansson K, Kvart C et al. Effects of naturally acquired decompensated mitral valve regurgitation on the renin-angiotensin-aldosterone system and atrial natriuretic peptide concentration in dogs. Am J Vet Res 1997; 58 (1): 77-82
• 16 Häggström J, Boswood A, O’Grady M et al. Effect of pimobendan or benazepril hydrochloride on survival times in dogs with congestive heart failure caused by naturally occurring myxomatous mitral valve disease: the QUEST study. J Vet Intern Med 2008; 22 (5): 1124-1235
• 17 Häggström J, Boswood A, O’Grady M et al. Longitudinal analysis of quality of life, clinical, radiographic, echocardiographic, and laboratory variables in dogs with myxomatous mitral valve disease receiving pimobendan or benazepril: the QUEST study. J Vet Intern Med 2013; 27 (6): 1441-1451
• 18 Hansson K, Häggström J, Kvart C et al. Left atrial to aortic root indices using two-dimensional and M-mode echocardiography in cavalier King Charles spaniels with and without left atrial enlargement. Vet Radiol Ultrasound 2002; 43 (6): 568-575
• 19 Hezzell MJ, Boswood A, Elliott J. Treatment of dogs with compensated degenerative mitral valve disease (DMVD) with spironolactone. Maastricht: ECVIM-CA Congress 2012 Im Internet: http://www.vin.com/Members/Proceedings/Proceedings.plx?CID=ECVIM2012&PID=pr84851&O=Generic Stand: 11/2014
• 20 Hungerbühler S, Henrich E. Die Mitralklappenendokardiose – aktueller Stand der Diagnose und Therapie. Kleintierprax 2014; 59 (6): 329-352
• 21 Hunt SA, Abraham WT, Chin MH et al. Focused update incorporated into the ACC/AHA 2005. Guidelines for the diagnosis and management of heart failure in adults. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation J Am Coll Cardiol 2009; 53 (15): e1-e90
• 22 Jepsen-Grant K, Pollard RE, Johnson LR. Vertebral heart scores in eight dog breeds. Vet Radiol Ultrasound 2013; 54 (1): 3-8
• 23 Kittleson M, Rishniw M, Pion P et al. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases. J Vet Intern Med 2009; 23 (3): 445-446; author reply 447–448
• 24 Kittleson MD, Bonagura JD. Re: Efficacy of spironolactone on survival in dogs with naturally occurring mitral regurgitation caused by myxomatous mitral valve disease. J Vet Intern Med 2010; 24 (6): 1245-1256 author reply 1247–1248
• 25 Kraetschmer S, Ludwig K, Meneses F et al. Vertebral heart scale in the beagle dog. J Small Anim Pract 2008; 49 (5): 240-243
• 26 Kvart C, Häggström J, Pedersen HD et al. Efficacy of enalapril for prevention of congestive heart failure in dogs with myxomatous valve disease and asymptomatic mitral regurgitation. J Vet Intern Med 2002; 16 (1): 80-88
• 27 Lamb CR, Wikeley H, Boswood A et al. Use of breed-specific ranges for the vertebral heart scale as an aid to the radiographic diagnosis of cardiac disease in dogs. Vet Rec 2001; 148 (23): 707-711
• 28 Lantis AC, Atkins CE, DeFrancesco TC. Aldosterone escape in furosemide-activated circulating renin-angiotensin-aldosterone system (RAAS) in normal dogs. J Vet Intern Med 2010; 24: 672
• 29 Lefebvre HP, Olliver E, Atkins CE et al. Safety of spironolactone in dogs with chronic heart failure because of degenerative valvular disease: a population-based, longitudinal study. J Vet Intern Med 2013; 27 (5): 1083-1091
• 30 Marcondes-Santos M, Tarasoutchi F, Mansur AP et al. Effects of carvedilol treatment in dogs with chronic mitral valvular disease. J Vet Intern Med 2007; 21 (5): 996-1001
• 31 Marin LM, Brown J, McBrien C et al. Vertebral heart size in retired racing Greyhounds. Vet Radiol Ultrasound 2007; 48 (4): 332-334
• 32 Moonarmart W, Boswood A, Luis Fuentes V et al. N-terminal pro B-type natriuretic peptide and left ventricular diameter independently predict mortality in dogs with mitral valve disease. J Small Anim Pract 2010; 51 (2): 84-96
• 33 Ouellet M, Bélanger MC, Difruscia R et al. Effect of pimobendan on echocardiographic values in dogs with asymptomatic mitral valve disease. J Vet Intern Med 2009; 23 (2): 258-263
• 34 Ovaert P, Elliott J, Bernay F et al. Aldosterone receptor antagonists – how cardiovascular actions may explain their beneficial effects in heart failure. J Vet Pharmacol Ther 2010; 33 (2): 109-117
• 35 Oyama MA. Neurohormonal activation in canine degenerative mitral valve disease: implications on pathophysiology and treatment. J Small Anim Pract 2009; 50 (Suppl 1): 3-11
• 36 Oyama MA, Levy RJ. Insights into serotonin signaling mechanisms associated with canine degenerative mitral valve disease. J Vet Intern Med 2010; 24 (1): 27-36
• 37 Pedersen HD, Koch J, Poulsen K et al. Activation of the renin-angiotensin system in dogs with asymptomatic and mildly symptomatic mitral valvular insufficiency. J Vet Intern Med 1995; 9 (5): 328-331
• 38 Pitt B. „Escape“ of aldosterone production in patients with left ventricular dysfunction treated with an angiotensin converting enzyme inhibitor: implications for therapy. Cardiovasc Drugs Ther 1995; 9 (1): 145-149
• 39 Pouchelon JL, Jamet N, Gouni V et al. Effect of benazepril on survival and cardiac events in dogs with asymptomatic mitral valve disease: a retrospective study of 141 cases. J Vet Intern Med 2008; 22 (4): 905-914
• 40 Reynolds CA, Brown DC, Rush JE et al. Prediction of first onset of congestive heart failure in dogs with degenerative mitral valve disease: the PREDICT cohort study. J Vet Cardiol 2012; 14 (1): 193-202
• 41 Schober KE, Hart TM, Stern JA et al. Detection of congestive heart failure in dogs by Doppler echocardiography. J Vet Intern Med 2010; 24 (6): 1358-1368
• 42 Schober KE, Hart TM, Stern JA et al. Effects of treatment on respiratory rate, serum natriuretic peptide concentration, and Doppler echocardiographic indices of left ventricular filling pressure in dogs with congestive heart failure secondary to degenerative mitral valve disease and dilated cardiomyopathy. J Am Vet Med Assoc 2011; 239 (4): 468-479
• 43 Tarnow I, Olsen LH, Kvart C et al. Predictive value of natriuretic peptides in dogs with mitral valve disease. Vet J 2009; 180 (2): 195-201
• 44 Unger T. The role of the renin-angiotensin system in the development of cardiovascular disease. Am J Cardiol 2002; 89 (2A): 3A-9A discussion 10A
• 45 Urabe Y, Mann DL, Kent RL et al. Cellular and ventricular contractile dysfunction in experimental canine mitral regurgitation. Circ Res 1992; 70 (1): 131-147
• 46 Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system Circulation 1991; 83 (6): 1849-1865